GSK's Blenrep Receives China's National Medical Products Administration Approval To Treat Adults With Relapsed Or Refractory Multiple Myeloma
غلاكسو سميث كلاين
ETF ذات القيمة السوقية الكبيرة للصين iShares
GlaxoSmithKline plc Sponsored ADR GSK | 0.00 | |
iShares China Large-Cap ETF FXI | 0.00 |
https://www.londonstockexchange.com/news-article/GSK/blenrep-approved-in-china-for-2l-multiple-myeloma/17553262